Therapy Areas: Diabetes
Xeris Pharmaceuticals starts dosing patients in phase two trial with ready-to-use, room-temperature stable liquid glucagon
18 March 2019 - United States-based Xeris Pharmaceuticals has started dosing patients in a phase two trial with its ready-to-use, room-temperature stable liquid glucagon in patients with Type one diab...
Xeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Ready-to-Use Glucagon to Address Exercise-Induced Hypoglycemia
15 March 2019 - - US-based specialty pharmaceutical company Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) has now begun dosing patients in a Phase 2 trial with its ready-to-use, room-temperature stable l...
Soleno Therapeutics Touts Positive Outcome from Planned Data Safety Monitoring Board Review of Phase III DESTINY PWS Clinical Trial of DCCR in Prader-Willi Syndrome
15 March 2019 - - A Data Safety Monitoring Board has recommended the continuation of US-based biopharmaceutical company Soleno Therapeutics, Inc.'s (NASDAQ: SLNO) Phase III trial in Prader-Willi ...
Genmab appoints Marisol Peron as new head of Communications and IR
12 March 2019 - Genmab A/S (CPH: GEN) announced on Monday the appointment of Marisol Peron as corporate vice president, Communications and Investor Relations, effective 11 March 2019.In her new role, ...
Sinclair Research, Turner Scientific Partner to Offer GLP Ototoxicity Testing Services
11 March 2019 - - US-based nonclinical services provider Sinclair Research and US-based nonclinical hearing research specialist Turner Scientific have formed an exclusive partnership to offer GLP...
Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia
11 March 2019 - - US-based Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) has dosed the first subjects in a Phase 1 clinical study of ARO-APOC3, an RNAi-based investigational medicine targeting Apolipo...
Related Headlines

Health Canada Approves Recordati Rare Diseases Canada's Cystadrops for Cystinosis Patients

CEL-SCI's Scientific Article on Vaccines for Autoimmune Disease Published in Journal of Clinical and Cellular Immunology

Innovus Pharma's Diabasens Product Approved in Canada Indicated to Relieve Cutaneous Pain Associated with Diabetic Neuropathy

US FDA expands approval of AstraZeneca's Farxiga and Xigduo XR

Neurogene Names Nagendran, Stankovic to Board of Directors

US FDA Approves Expanded Farxiga and Xigduo XR Labels for Use in Patients with Type 2 Diabetes and Moderate Renal Impairment

Sanofi wins US FDA approval for the expanded use of Soliqua 100/33 as add-on to diet and exercise for adults with type 2 diabetes

Astra Zeneca's Brilinta Phase III Themis trial meets primary endpoint

Ironwood Pharmaceuticals Planned R and D Spin-off, Cyclerion, Secures Commitments of USD 175m

Eisai Inc submits sNDA with US FDA to update the labeling of anti-obesity agent BELVIQ (lorcaserin HCl)

AstraZeneca reports meeting of primary end point by Brilinta's phase III THEMIS trial

Phase 1 Data Published in Nature Communications Show Potential of mRNA Encoding VEGF-A as a Regenerative Therapeutic

Hygieia awarded US FDA's 510(k) clearance for first Phone App to enhance its Nav Insulin Guidance Service

Boehringer Ingelheim and Lilly's CAROLINA Cardiovascular Outcome Trial for Trajenta Meets Primary Endpoint of Non-Inferiority Compared to Glimepiride

The US FDA authorises marketing of first interoperable insulin pump to allow patients to customise treatment through individual diabetes devices